TAFAMIDIS: 9,202 Adverse Event Reports & Safety Profile
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
9,202
Total FAERS Reports
3,343 (36.3%)
Deaths Reported
2,284
Hospitalizations
9,202
As Primary/Secondary Suspect
95
Life-Threatening
62
Disabilities
May 3, 2019
FDA Approved
Pfizer Laboratories Div Pfi...
Manufacturer
Prescription
Status
Manufacturer: Pfizer Laboratories Div Pfizer Inc · FDA Application: 212161 ·
Patent Expires: Dec 19, 2026 · First Report: 19870101 · Latest Report: 20250926
What Are the Most Common TAFAMIDIS Side Effects?
#1 Most Reported
Death
2,553 reports (27.7%)
#2 Most Reported
Dyspnoea
608 reports (6.6%)
#3 Most Reported
Off label use
571 reports (6.2%)
All TAFAMIDIS Side Effects by Frequency
| Side Effect | Reports | % of Total | Deaths | Hosp. |
|---|---|---|---|---|
| Death | 2,553 | 27.7% | 2,510 | 213 |
| Dyspnoea | 608 | 6.6% | 98 | 248 |
| Off label use | 571 | 6.2% | 218 | 157 |
| Cardiac failure | 444 | 4.8% | 196 | 205 |
| Fatigue | 438 | 4.8% | 45 | 114 |
| Fall | 372 | 4.0% | 87 | 240 |
| Malaise | 301 | 3.3% | 38 | 85 |
| Hypoacusis | 298 | 3.2% | 30 | 44 |
| Atrial fibrillation | 296 | 3.2% | 41 | 107 |
| Asthenia | 256 | 2.8% | 45 | 125 |
| Dizziness | 255 | 2.8% | 16 | 75 |
| Weight decreased | 253 | 2.8% | 67 | 119 |
| Cardiac failure congestive | 241 | 2.6% | 114 | 125 |
| Cardiac disorder | 234 | 2.5% | 62 | 114 |
| Cerebrovascular accident | 219 | 2.4% | 35 | 114 |
| Condition aggravated | 217 | 2.4% | 55 | 79 |
| Covid-19 | 216 | 2.4% | 52 | 102 |
| Product dose omission issue | 215 | 2.3% | 43 | 97 |
| Illness | 207 | 2.3% | 32 | 82 |
| Peripheral swelling | 195 | 2.1% | 27 | 100 |
Who Reports TAFAMIDIS Side Effects? Age & Gender Data
Gender: 20.7% female, 79.3% male. Average age: 80.7 years. Most reports from: US. View detailed demographics →
Is TAFAMIDIS Getting Safer? Reports by Year
| Year | Reports | Deaths | Hosp. |
|---|---|---|---|
| 2002 | 1 | 0 | 1 |
| 2006 | 1 | 0 | 0 |
| 2011 | 1 | 0 | 0 |
| 2014 | 2 | 0 | 0 |
| 2015 | 1 | 0 | 0 |
| 2016 | 2 | 1 | 1 |
| 2017 | 1 | 1 | 1 |
| 2018 | 13 | 1 | 4 |
| 2019 | 40 | 9 | 20 |
| 2020 | 308 | 144 | 95 |
| 2021 | 436 | 208 | 111 |
| 2022 | 675 | 345 | 233 |
| 2023 | 920 | 425 | 336 |
| 2024 | 978 | 488 | 302 |
| 2025 | 347 | 160 | 115 |
What Is TAFAMIDIS Used For?
| Indication | Reports |
|---|---|
| Cardiac amyloidosis | 2,450 |
| Amyloidosis | 2,264 |
| Acquired attr amyloidosis | 662 |
| Cardiac disorder | 255 |
| Amyloidosis senile | 222 |
| Product used for unknown indication | 177 |
| Cardiomyopathy | 163 |
| Cardiac failure | 117 |
| Cardiac failure congestive | 112 |
| Familial amyloidosis | 64 |
TAFAMIDIS vs Alternatives: Which Is Safer?
TAFAMIDIS vs TAFAMIDIS MEGLUMINE
TAFAMIDIS vs TAFASITAMAB
TAFAMIDIS vs TAFASITAMAB-CXIX
TAFAMIDIS vs TAFINLAR
TAFAMIDIS vs TAFLUPROST
TAFAMIDIS vs TAGRAXOFUSP-ERZS
TAFAMIDIS vs TAHOR
TAFAMIDIS vs TALAZOPARIB
TAFAMIDIS vs TALC
TAFAMIDIS vs TALIGLUCERASE ALFA
Official FDA Label for TAFAMIDIS
Official prescribing information from the FDA-approved drug label.